The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities
Open accessAbstract
Detection of small hepatocellular carcinoma (HCC) eligible for curative treatment is increased by surveillance, but its optimal periodicity is still debated. Thus, this randomized trial compared two ultrasonographic (US) periodicities: 3 months versus 6 months. A multicenter randomized trial was conducted in France and Belgium (43 sites). Patients with histologically proven compensated cirrhosis were randomized into two groups: US every 6 months (Gr6M) or 3 months (Gr3M). For each focal lesion detected, diagnostic procedures were performed according to European Association for the Study of the Liver guidelines. Cumulative incidence of events was estimated, then compared using Gray's test. The prevalence of HCC ≤30 mm in diameter was the main endpoint. A sample size of 1,200 patients was required. A total of 1,278 patients were randomized (Gr3M, n = 640; Gr6M, n = 638; alcohol 39.2%, hepatitis C virus 44.1%, hepatitis B virus 12.5%). At least one focal lesion was detected in 358 patients (28%) but HCC was confirmed in only 123 (9.6%) (uninodular 58.5%, ≤30 mm in diameter 74%). Focal-lesion incidence was not different between Gr3M and Gr6M groups (2-year estimates, 20.4% versus 13.2%, P = 0.067) but incidence of lesions ≤10 mm was increased (41% in Gr3M versus 28% in Gr6M, P = 0.002). No difference in either HCC incidence ( P = 0.13) or in prevalence of tumors ≤30 mm in diameter (79% versus 70%, P = 0.30) was observed between the randomized groups. Conclusion: US surveillance, performed every 3 months, detects more small focal lesions than US every 6 months, but does not improve detection of small HCC, probably because of limitations in recall procedures. (Hepatology 2011;)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Self-citationMoher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Moher, D. (2001) · JAMA · doi:10.1001/jama.285.15.1987 · Cited by 2,545
de Franchis, R. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.004 · Cited by 2,281
Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., Camerini, T., Roayaie, S., Schwartz, M. E., Grazi, G. L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70284-5 · Cited by 2,045
Randomized controlled trial of screening for hepatocellular carcinoma
Zhang, B.-H., Yang, B.-H., & Tang, Z.-Y. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0552-0 · Cited by 1,496
Forner, A., Vilana, R., Ayuso, C., Bianchi, L., Solé, M., Ayuso, J. R., Boix, L., Sala, M., Varela, M., Llovet, J. M., et al. (2008) · Hepatology · doi:10.1002/hep.21966 · Cited by 1,032
de Franchis, R. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.05.009 · Cited by 1,029
SINGAL, A., VOLK, M. L., WALJEE, A., SALGIA, R., HIGGINS, P., ROGERS, M. A. M., & MARRERO, J. A. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04014.x · Cited by 819
Hepatocellular Carcinoma in Italian Patients with Cirrhosis
Colombo, M., de Franchis, R., Del Ninno, E., Sangiovanni, A., De Fazio, C., Tommasini, M., Donato, M. F., Piva, A., Di Carlo, V., & Dioguardi, N. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109053251002 · Cited by 813
N'Kontchou, G., Mahamoudi, A., Aout, M., Ganne-Carrié, N., Grando, V., Coderc, E., Vicaut, E., Trinchet, J. C., Sellier, N., Beaugrand, M., et al. (2009) · Hepatology · doi:10.1002/hep.23181 · Cited by 450
Self-citationSangiovanni, A., Manini, M. A., Iavarone, M., Romeo, R., Forzenigo, L. V., Fraquelli, M., Massironi, S., Della Corte, C., Ronchi, G., Rumi, M. G., et al. (2010) · Gut · doi:10.1136/gut.2009.187286 · Cited by 408
Hepatocellular Carcinoma: Epidemiology, Risk Factors, and Screening
Sherman, M. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871194 · Cited by 404
Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis
Sherman, M. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247128 · Cited by 396
Santi, V., Trevisani, F., Gramenzi, A., Grignaschi, A., Mirici-Cappa, F., Poggio, P. D., Nolfo, M. A. D., Benvegnù, L., Farinati, F., Zoli, M., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.03.010 · Cited by 304
Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis
Pateron, D., Ganne, N., Trinchet, J. C., Aurousseau, M. H., Mal, F., Meicler, C., Coderc, E., Reboullet, P., & Beaugrand, M. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80468-4 · Cited by 296
Self-citationSherman, M. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00025-3 · Cited by 270
Yu, N. C., Chaudhari, V., Raman, S. S., Lassman, C., Tong, M. J., Busuttil, R. W., & Lu, D. S. K. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.09.017 · Cited by 265
Andersson, K. L., Salomon, J. A., Goldie, S. J., & Chung, R. T. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.005 · Cited by 242
Siegelman, E. S., & Rosen, M. A. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-12930 · Cited by 208
Surveillance of cirrhosis for hepatocellular carcinoma: a cost–utility analysis
Coon, J. T., Rogers, G., Hewson, P., Wright, D. E., Anderson, R., Jackson, S., Ryder, S. D., Cramp, M., & Stein, K. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604301 · Cited by 123
Chan, A. C. Y., Poon, R. T. P., Ng, K. K., Lo, C. M., Fan, S. T., & Wong, J. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31816a747a · Cited by 92
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationLlovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“However, the unique randomized study comparing 3 versus 6-month based programs failed to detect any differences [91].”
BackgroundA global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Metadata
- Authors
- Trinchet, J.-C., Chaffaut, C., Bourcier, V., Degos, F., Henrion, J., Fontaine, H., Roulot, D., Mallat, A., Hillaire, S., Cales, P., Ollivier, I., Vinel, J.-P., Mathurin, P., Bronowicki, J.-P., Vilgrain, V., N'Kontchou, G., Beaugrand, M., & Chevret, S.
- Venue
- Hepatology
- Published
- 2010-12
- Volume
- 54
- Issue
- 6
- Pages
- 1987-1997
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1996109529
- Cited by
- 400
- References
- 25
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.